Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
View Patent ↗In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject. In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
1. A method of treating a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy in a patient in need comprising administering to said patient a therapeutically effective amount of an inhibitor of an alternative (ALT) non-homologous end joining (NHEJ) factor.
2. The method of claim 1 , wherein the inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor is a Poly [ADP-Ribose] Polymerase 1 (PARP1) inhibitor or a DNA ligase IIIα inhibitor.
3. The method of claim 1 , wherein said patient is treated with a combination of a PARP1 inhibitor and a DNA ligase IIIα inhibitor.
4. The method of claim 1 , wherein said patient's breast cancer tumor also under-expresses one or more DNA-PK-dependent NHEJ factors.
5. The method of claim 4 , wherein said patient's breast cancer tumor under-expresses Ku70 and DNA Ligase IV.
6. The method of claim 1 , wherein said patient's breast cancer tumor is also resistant to anti-HER2 therapies.
7. The method of claim 1 , wherein the PARP inhibitor ABT888 and at least one DNA ligase IIIα inhibitor selected from the group consisting of L67, L-67-5, L67-6 and GEG54 are co-administered to said patient.
8. The method of claim 3 , wherein the PARP1 inhibitor and a DNA ligase IIIα inhibitor are co-administered to said patient.
9. The method of claim 1 , wherein the PARP1 inhibitor is selected from the group consisting of nicotinamide; NU1025; 3-aminobenzamide; 4-amino-1,8-naphthalimide; 1,5-isoquinolinediol; 6(5H)-phenanthriddinone; 1,3,4,5,-tetrahydrobenzo(c)(1,6)- and (c)(1,7)-naphthyridin-6 ones; adenosine substituted 2,3-dihydro-1H-isoindol-1-ones; AG14361; AG014699; 2-(4-chlorophenyl)-5-quinoxalinecarboxamide; 5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone; isoindolinone derivative INO-1001; 4-hydroxyquinazoline; 2-[3-[4-(4-chlorophenyl) 1-piperazinyl]propyl]-4-3(4)-quinazolinone; 1,5-dihydroxyisoquinoline (DHIQ); 3,4-dihydro-5 [4-(1-piperidinyl)(butoxy)-1(2H)-isoquinolone; CEP-6800; GB-15427; PJ34; DPQ; BS-201; AZD2281 (Olaparib); BS401; CHP101; CHP102; INH2BP; BSI201; BSI401; TIQ-A; an imidazobenzodiazepine; 8-hydroxy-2-methylquinazolinone (NU1025), CEP 9722, MK 4827, LT-673; 3-aminobenzamide; Olaparib (AZD2281; ABT-888 (Veliparib); BSI-201 (Iniparib); Rucaparib (AG-014699); INO-1001; A-966492; PJ-34; and PARP1 inhibitors described in U.S. Patent Application Document No 20100099683 (Ser. No. 12/576,410), entitled “Compounds that Inhibit Human DNA Ligases and Methods of Treating Cancer”.
10. The method of claim 3 , wherein ABT888 and at least one DNA ligase IIIα inhibitor selected from the group consisting of L67, L-67-5, L67-6 and GEG54 are administered to said patient.
11. A method of treating an anti-estrogen-naive breast cancer tumor whose cells over-express one or more ALT NHEJ factors in a patient in need comprising co-administering to said patient a therapeutically effective amount of a PARP1 inhibitor and a DNA ligase IIIα inhibitor.
12. The method of claim 11 , wherein the ALT NHEJ factors are PARP1 and DNA ligase IIIα.
13. A method of treating an anti-estrogen-naive breast cancer tumor whose cells over-express one or more ALT NHEJ factors and under-express one or more DNA-PK-dependent NHEJ factors in a patient in need comprising co-administering a therapeutically effective amount of a PARP1 inhibitor and a DNA ligase IIIα inhibitor to said patient.
14. The method of claim 13 , wherein the ALT NHEJ factors are PARP1 and DNA ligase IIIα and the DNA-PK-dependent NHEJ factors are Ku70 and DNA Ligase IV.
15. A method of treating an anti-estrogen-naive breast cancer tumor whose cells, based on an evaluation of clinical factors selected from the group consisting of mammogram evaluation, breast MRI evaluation, ultrasound evaluation, age, fractures, bone mineral density screening, Chronic Disease Scores, and co-morbidities, are considered likely to over-express one or more ALT NHEJ factors in a patient in need comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to said patient.
16. The method of claim 15 , wherein the ALT NHEJ factors are PARP1 and DNA ligase IIIα.
17. A method of treating an anti-estrogen-naive breast cancer tumor whose cells, based on an evaluation of clinical factors selected from the group consisting of mammogram evaluation, breast MRI evaluation, ultrasound evaluation, age, fractures, bone mineral density screening, Chronic Disease Scores, and co-morbidities, are considered likely to over-express one or more ALT NHEJ factors and to under-express one or more DNA-PK-dependent NHEJ factors in a patient in need comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to said patient.
18. The method of claim 17 , wherein the ALT NHEJ factors are PARP1 and DNA ligase III and the DNA-PK-dependent NHEJ factors are Ku70 and DNA Ligase IV.
19. A method of treating a treatment-naive breast cancer tumor whose cells over-express one or more ALT NHEJ factors in a patient in need comprising co-administering to said patient a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor.
20. The method of claim 19 , wherein the ALT NHEJ factors are PARP1 and DNA ligase IIIα.
21. A method of treating a treatment-naive breast cancer tumor whose cells over-express one or more ALT NHEJ factors and under-express one or more DNA-PK-dependent NHEJ factors in a patient in need comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to said patient.
22. The method of claim 21 , wherein the ALT NHEJ factors are PARP1 and DNA ligase III and the DNA-PK-dependent NHEJ factors are Ku70 and DNA Ligase IV.
23. A nucleic acid array for expression-based classification of a breast cancer tumor as being either responsive or non-responsive to anti-estrogen mono or co-therapy, the array comprising at least 10 probes immobilized on a solid support, each of the probes:
(a) having a length of between about 25 to about 50 or more nucleotides; and
(b) being derived from sequences corresponding to, or complementary to, transcripts or partial transcripts of each member of one or more prognostic gene sets comprised of genes encoding PARP1, DNA ligase IIIα, Ku70 or DNA ligase IV.
24. A method of treating a pancreatic cancer which is non-responsive to chemotherapy and/or radiation in a patient in need comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to said patient.
25. The method of claim 24 , wherein the PARP1 inhibitor and a DNA ligase IIIα inhibitor are co-administered to said patient and said patient cannot tolerate either chemotherapy or radiation.
26. The method of claim 25 , wherein the PARP inhibitor ABT888 and at least one DNA ligase IIIα inhibitor selected from the group consisting of L67, L-67-5, L67-6 and GEG54 are co-administered to said patient.
27. The method of claim 24 , wherein the PARP1 inhibitor is selected from the group consisting of nicotinamide; NU1025; 3-aminobenzamide; 4-amino-1,8-naphthalimide; 1,5-isoquinolinediol; 6(5H)-phenanthriddinone; 1,3,4,5,-tetrahydrobenzo(c)(1,6)- and (c)(1,7)-naphthyridin-6 ones; adenosine substituted 2,3-dihydro-1H-isoindol-1-ones; AG14361; AG014699; 2-(4-chlorophenyl)-5-quinoxalinecarboxamide; 5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone; isoindolinone derivative INO-1001; 4-hydroxyquinazoline; 2-[3-[4-(4-chlorophenyl) 1-piperazinyl]propyl]-4-3(4)-quinazolinone; 1,5-dihydroxyisoquinoline (DHIQ); 3,4-dihydro-5 [4-(1-piperidinyl)(butoxy)-1(2H)-isoquinolone; CEP-6800; GB-15427; PJ34; DPQ; BS-201; AZD2281 (Olaparib); BS401; CHP101; CHP102; INH2BP; BSI201; BSI401; TIQ-A; an imidazobenzodiazepine; 8-hydroxy-2-methylquinazolinone (NU1025), CEP 9722, MK 4827, LT-673; 3-aminobenzamide; Olaparib (AZD2281; ABT-888 (Veliparib); BSI-201 (Iniparib); Rucaparib (AG-014699); INO-1001; A-966492 PJ-34 and mixtures thereof.
28. A method of treating a chemotherapy and/or radiation-naive pancreatic cancer in a patient in need comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to said patient, wherein the pancreatic cancer cells, based on an evaluation of clinical factors selected from the group consisting of age, tumor size, abdominal pain, weight loss, jaundice, insulin and/or lipid imbalances and co-morbidities, are considered likely to over-express one or more ALT NHEJ factors.